UK markets closed

Ipsen S.A. (IPSEF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
88.500.00 (0.00%)
At close: 04:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • P
    Paul
    Any follows Onivyde - 2L SCLC trial?
  • y
    yiehom
    I like this sudden drop in a share price. It makes it a perfect value candidate on my watch list. Brilliant fundamentals: ROE, rev. growth and Cash Flows. What else?
  • K
    Kevin
    Need a current update. Stock has been under pressure for the past year due to generic concerns. Management has failed to allay fears.
  • C
    Country Squire
    Sales growth of 22.6% in 3rd qtr 2017! Find me another BioScience Pharmaceutical company producing at this level... any ??
  • A
    Aksel
    Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a partial clinical hold effective immediately, for the pediatric population under the age of 14 was issued for studies conducted under IND120181... Great article here about IPSEY https://marketwirenews.com/news-releases/ipsen-initiates-partial-clinical-hold-for-palovarote-8394020785395819.html?i=c
    Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a.
    Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a.
    marketwirenews.com
  • K
    Kevin
    What is current outlook?
  • C
    Country Squire
    Onc Sales up higher than any other Oncology Company -globally! 19% - Average across Oncology peers is ~ 8-10% Sky is the limit in 2017-2018 for Ipsen in Oncology. See Excelis' recent hepatic and RCC trial success in partnership with Ipsen. Huge market opportunity
  • C
    Country Squire
    Yeah - this makes sense. Ipsen delivers some of the strongest financial growth in the industry... and the stock goes down -- Yep, makes perfect sense